These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4170420)

  • 41. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
    Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
    BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relative amount of epithelium, muscle, connective tissue and lumen in prostatic hyperplasia as a function of the mass of tissue resected.
    Schuster GA; Schuster TG
    J Urol; 1999 Apr; 161(4):1168-73. PubMed ID: 10081863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ultrastructural and biochemical expressions of divergent differentiation in prostates of castrated dogs treated with estrogen and androgen.
    Merk FB; Ofner P; Kwan PW; Leav I; Vena RL
    Lab Invest; 1982 Nov; 47(5):437-50. PubMed ID: 6182388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Indications of antiandrogens in benign hyperplasia of the prostate].
    Benassayag E
    J Urol (Paris); 1995; 101(2):109-10. PubMed ID: 8522854
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.
    Niżański W; Levy X; Ochota M; Pasikowska J
    Reprod Domest Anim; 2014 Jun; 49 Suppl 2():8-15. PubMed ID: 24947855
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome.
    Svindland A; Eri LM; Tveter KJ
    Scand J Urol Nephrol Suppl; 1996; 179():113-7. PubMed ID: 8908676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
    Nishiyama T; Tomita Y; Takahashi K
    Urology; 2004 May; 63(5):917-21. PubMed ID: 15134981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.
    Trachtenberg J; Hicks LL; Walsh PC
    J Clin Invest; 1980 May; 65(5):1051-9. PubMed ID: 6154062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benign hyperplasia of the human prostate exposed to steroid hormones in organ culture.
    Harbitz TB; Falkanger B; Sander S
    Acta Pathol Microbiol Scand Suppl; 1974; Suppl 248():89-93. PubMed ID: 4141577
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of androgen deprivation on prostate alpha 1-adrenergic receptors.
    Lacey JP; Donatucci CF; Price DT; Page SO; Bennett SA; Tenniswood MP; Schwinn DA
    Urology; 1996 Aug; 48(2):335-41. PubMed ID: 8753753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
    Umeda K
    Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical treatment of benign prostatic hyperplasia: the effect of surgical or medical castration.
    Schröder FH
    Prog Clin Biol Res; 1994; 386():191-6. PubMed ID: 7528386
    [No Abstract]   [Full Text] [Related]  

  • 54. Ultrastructural and histochemical studies of the prostate of dog under cyproterone acetate.
    Hohbach C
    Invest Urol; 1977 Sep; 15(2):117-22. PubMed ID: 71282
    [No Abstract]   [Full Text] [Related]  

  • 55. Antiandrogen effects on canine prostatic secretion.
    Schoonees R; Reynoso G; De Klerk JN; Murphy GP
    Invest Urol; 1973 May; 10(6):434-7. PubMed ID: 4704168
    [No Abstract]   [Full Text] [Related]  

  • 56. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
    Drewa T; Chlosta P
    Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
    [No Abstract]   [Full Text] [Related]  

  • 57. Testosterone-induced DNA synthesis in cultured rat ventral prostate. I. Effects of cyproterone acetate.
    Buchanan LJ; Riches AC
    J Anat; 1986 Oct; 148():159-67. PubMed ID: 2961721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of the steroidal androgen receptor antagonist Win 49,596 on steroid-induced benign prostatic hyperplasia in the castrate beagle dog.
    Juniewicz PE; Lemp BM; Barbolt TA; LaBrie TK; McCarthy M; Reel JR; Batzold FH
    Prostate; 1990; 16(1):1-14. PubMed ID: 1689481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer.
    Zhang L; Zhou J; Fan S; Liang CZ
    Asian J Androl; 2016; 18(4):654-6. PubMed ID: 26208396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.